Drug Search Results
More Filters [+]

ST-1898

Alternative Names: st-1898, st 1898, st1898
Latest Update: 2024-04-11
Latest Update Note: Clinical Trial Update

Product Description

ST-1898 is a drug candidate being developed by Scitech Pharma, which acts as a tyrosine kinase inhibitor for the treatment of solid tumors. (Sourced from: http://www.scitech-mq.com.cn/en/contents/1115/1322.html)

Mechanisms of Action: VEGFR2 Inhibitor,C-Met Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Beijing Saite Mingqiang Pharmaceutical Technology Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ST-1898

Countries in Clinic: China

Active Clinical Trial Count: 5

Highest Development Phases

Phase 2: Melanoma|Renal Cell Carcinoma|Thyroid Cancer

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ST-1898-201

P2

Recruiting

Renal Cell Carcinoma

2025-12-01

ST-1898-202

P2

Recruiting

Thyroid Cancer

2025-12-01

ST-1898-203

P2

Recruiting

Melanoma

2025-09-01

CTR20230114

P2

Not yet recruiting

Renal Cell Carcinoma

None

Recent News Events

Date

Type

Title